INGN · Inogen
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $6.38
Note written ·
Price against the kill line
10.8% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $6.38, on record since 11 November 2026. The shares are down 0.4% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $6.38, above both the 50-day and 200-day moving averages and the post-report closes, would show the shares leading the S&P 500 and prove this call wrong; so would fourth-quarter 2026 revenue above the $68 million top of the guide.
Research onlyNot in the portfolio.
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 9 November 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 77.2
- Revenue, change on a year (%)
- −2.4
- Gross margin (%)
- 44.1
- Operating margin (%)
- −20.2
- Free cash flow, four quarters ($M)
- −11.3
- Net cash, cash less debt ($M)
- 96.8
- Free-cash-flow yield (%)
- −7.7
All filed numbers
What Inogen reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 77.2 | −2.4 | 44.1 | −20.2 |
| first filed | 95.1 | +3.0 | 45.5 | −5.4 |
| first filed | 85.1 | +3.4 | 44.5 | −11.0 |
| first filed restated | 79.1 | −11.0 | 45.7 | −6.9 |
| first filed | 92.3 | +4.0 | 44.8 | −6.6 |
| Pre-tax income ($M) | −14.6 |
| Net income ($M) four quarters: −35.5 | −16.2 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | −2.3 |
| Operating cash flow ($M) | −9.2 |
| Capital spending ($M) | 2.2 |
| Free cash flow ($M) | −11.3 |
| Cash and short-term investments ($M) | 96.8 |
| Debt ($M) | None reported |
| Net cash, cash less debt ($M) no debt reported | 96.8 |
| Deferred revenue ($M) −36.5% on a year | 2.6 |
| Backlog, orders not yet delivered ($M) at 31 December 2025, filed 27 February 2026; −33.0% on a year | 1.1 |
| Receivables ($M) | 48.6 |
| Inventory ($M) | 29.0 |
| Shareholders' equity ($M) | 157 |
| Market value ($M) | 148 |
| Enterprise value, market value plus net debt ($M) no debt reported | 51.1 |
| Enterprise value to sales (×) | Not available |
| Enterprise value to operating income (×) | Not available |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 0.9 |
| Free-cash-flow yield (%) | −7.7 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 5.9% of shares outstanding sold short, 4.1 days of average trading to cover, +3.9% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $0 |
| 12 monthsfrom | $0 | $143K |
The thesis
Inogen's shares are more likely to lag the S&P 500 than to beat it over the next three months. Its first report as a pure oxygen-concentrator maker, on 5 November 2026, showed revenue down 2.4% and a lower outlook. The company also replaced its chief executive officer (CEO) that day. The case now rests on a $20 million cost program and $97.7 million of cash. The fourth-quarter report, expected around February 2027, shows whether losses narrow and international sales recover.
Third-quarter revenue from continuing operations was $77.2 million, against $79.1 million a year earlier, and fell 3.2% in constant currency (company release, 5 November 2026). The company guided fourth-quarter revenue to $65 million–$68 million and full-year 2026 revenue to $298 million–$301 million. It replaced an adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) target of about $4 million with a full-year adjusted loss from continuing operations of $7 million–$8 million (Earnings Whispers, 5 November 2026). The new CEO, Andy Reding, said on the call: "These results are not where they need to be, and we are taking action to improve them."
The market has repriced the report. The shares closed at $5.75 on 11 November 2026, below the $7.22 close of 4 November 2026, the last session before the results, and the 3-month change is −1.0%. That price assumes the lower guide holds. Results that beat it would test the call.
Bullish and bearish views on Inogen, Inc
The bull case on Inogen, Inc (INGN), in brief: US sales returned to growth. The bear case: international sales reversed sharply.
Bull case
- US sales returned to growth. US sales were $42.2 million in the third quarter of 2026, up 3.8% year on year (company release, 5 November 2026). Management said on the 5 November 2026 call that this was the first growth since the fourth quarter of 2024, and that it expects US growth to speed up in the fourth quarter.
- The rental sale has closed. The sale of the US oxygen rental business to Rotech Healthcare closed on 2 November 2026, with estimated cash consideration of up to $24.8 million, expected in the first half of 2027 (company release, 5 November 2026). It comes with a long-term supply agreement for Inogen's concentrators.
- Costs are coming down. A program begun in the fourth quarter of 2026 targets about $20 million of annual savings by the end of 2027, with the first $10 million due before the end of 2026 (5 November 2026 call). Management expects more than $40 million of annual operating expense savings against the pre-sale run rate, once the divestiture is counted.
- Cash with no debt. Cash, marketable securities and restricted cash totaled $97.7 million on 30 September 2026, with no debt outstanding (company release, 5 November 2026).
- The company is buying back stock. Inogen repurchased 1,786,850 shares for $11.2 million in 2026 through the third-quarter report, and raised its authorization by $15 million to $45 million (company release, 5 November 2026).
Bear case
- International sales reversed sharply. International sales were $34.9 million in the third quarter of 2026, down 9.0% and down 10.4% in constant currency, after a rise of about 15% in the second quarter (company release, 5 November 2026; Earnings Whispers, 5 November 2026). Management blamed softer capital spending and inventory management at large European customers and expects that to continue into the fourth quarter.
- The outlook keeps moving lower. The $65 million–$68 million fourth-quarter guide sits below the $77.2 million just reported (company release, 5 November 2026). The full-year guide had been $366 million–$373 million at the start of 2026 and $355 million–$361 million in August, both before the rental business was split out (Earnings Whispers, 5 November 2026).
- Revenue missed estimates. Revenue of $77.2 million compared with a $92.25 million estimate (Benzinga, 5 November 2026). Those estimates appear to include rental revenue, which was $11.6 million in the second quarter, and that amount does not close the whole gap.
- Losses are wider and margin is lower. The loss from continuing operations under generally accepted accounting principles was $14.8 million, against $3.6 million a year earlier, including a $10.6 million goodwill impairment (company release, 5 November 2026). Adjusted gross margin fell to 44.2%, from 45.6% in the second quarter and 45.9% a year earlier.
- Cash is shrinking. The cash total fell to $97.7 million on 30 September 2026 from $106.8 million on 30 June 2026. Third-quarter operating cash flow was about negative $4.5 million, after positive $2.9 million in the second quarter, driven by a working-capital build (company releases; Earnings Whispers, 5 November 2026).
- Leadership and yardsticks both changed. Reding, who joined as chief operating officer in July, succeeded Kevin Smith as CEO on 5 November 2026. The company moved its main profit measure to adjusted net earnings without giving a dated profit target (5 November 2026 call).
Price setup
The shares closed at $7.22 on 4 November 2026, $6.77 on 5 November 2026 and $6.03 on 6 November 2026, as the report and the lower guide were absorbed (adjusted daily closes). Earnings Whispers noted on 5 November 2026 that the shares had risen 22.5% between the August report and the $7.22 close, so the post-report drop gave back most of that run.
The last close was $5.75 on 11 November 2026. That sits below the 50-day moving average of $5.99 and the 200-day moving average of $6.24, both as of 11 November 2026. A recovery above both averages would be the first price sign that the market is looking past the guide cut.
The 52-week high is $7.67, set intraday on 28 April 2026, and the last close is 25.0% below it. The 52-week closing low is $5.09, from 23 September 2026, just before the divestiture announcement. The 3-month change is −1.0%, measured from the $5.81 close of 13 August 2026.
Catalysts ahead
- ~31 December 2026 (est.): Deadline for completing the first $10 million of the cost program. It is the first check on whether the new CEO's savings arrive on the schedule given on the 5 November 2026 call.
- ~25 February 2027 (est.): Fourth-quarter 2026 report; the company has not announced the date. It tests the $65 million–$68 million revenue guide and the $7 million–$8 million adjusted loss guide, and shows whether international sales have recovered.
- ~30 June 2027 (est.): Latest expected receipt of the up to $24.8 million rental sale proceeds, which the company places in the first half of 2027. The final amount and timing show how much cash the divestiture adds to the $97.7 million reported for 30 September 2026.
What would change the view
A daily close above $6.38, above both the 50-day and 200-day moving averages and the post-report closes, would show the shares leading the S&P 500 and prove this call wrong; so would fourth-quarter 2026 revenue above the $68 million top of the guide.
What it trades with
Recent moves in the shares trace to company events: the 30 September 2026 divestiture announcement and the 5 November 2026 report. The outside drivers named by management are capital spending and inventory decisions at large European customers. Currency also matters: it narrowed the third-quarter revenue decline to 2.4% from 3.2% in constant currency. Rotech's demand is a further link, through the long-term supply agreement that came with the 2 November 2026 closing.
The evidence, claim by claim (8)
- Third-quarter 2026 revenue from continuing operations was $77.2 million, down 2.4% from $79.1 million and down 3.2% in constant currency. Inogen Q3 2026 results release · as of
- Third-quarter 2026 US sales were $42.2 million, up 3.8%, and international sales were $34.9 million, down 9.0%. Inogen Q3 2026 results release · as of
- Guidance from continuing operations is fourth-quarter revenue of $65 million–$68 million, full-year 2026 revenue of $298 million–$301 million and a full-year adjusted loss of $7 million–$8 million. Inogen Q3 2026 results release · as of
- The loss from continuing operations was $14.8 million against $3.6 million a year earlier, including a $10.6 million goodwill impairment; adjusted gross margin was 44.2% against 45.9% a year earlier. Inogen Q3 2026 results release · as of
- Cash, marketable securities and restricted cash totaled $97.7 million with no debt; third-quarter operating cash flow was about negative $4.5 million. Inogen Q3 2026 results release and earnings call · as of
- The US oxygen rental business sale to Rotech Healthcare closed with estimated cash consideration of up to $24.8 million, expected in the first half of 2027. Inogen Q3 2026 results release · as of
- A cost program targets about $20 million of annual savings by the end of 2027, with the first $10 million due before the end of 2026. Inogen Q3 2026 earnings call · as of
- Andy Reding, the chief operating officer, was appointed President and CEO, succeeding Kevin Smith. Inogen Q3 2026 results release · as of
Sources
- Inogen Announces Third Quarter 2026 Financial Results · stocktitan.net ·
- Inogen (INGN) Q3 2026 Earnings Call Transcript · fool.com ·
- Finviz ·
- Inogen Announces Third Quarter 2026 Financial Results · morningstar.com ·
Related · shared themes
AZTA
Azenta
Azenta is more likely to beat the S&P 500 over three months because its fiscal 2027 plan, issued 10 November 2026, adds 3% to 5% organic…
AVTR
Avantor
Avantor's lab-supply volumes are growing again, with Q3 2026 organic growth of 5.2% and a raised FY2026 outlook, but distribution margins…
CRL
Charles River Laboratories International
Charles River Laboratories' preclinical recovery passed its 4 November 2026 test with 4.7% organic growth, a 1.09 book-to-bill and raised…
EMBC
Embecta
Embecta Corp. shares are modestly favored to beat the S&P 500 as higher margins and debt repayment outweigh shrinking U.S. pen-needle…
See also · stocks to watch